Biological Warfare
VGX Pharmaceuticals Receives $1.9 Million Contract from U.S. Government to Develop Skin Micro-Electroporation for Improved Biodefense Vaccine Efficacy
Published in Vaccine Weekly, September 26th, 2007
VGX Pharmaceuticals announced that it has been awarded a contract from the Defense Threat Reduction Agency (DTRA) to develop VGX's constant current electroporation technology for intradermal (ID) delivery of DNA vaccines and therapeutics. The contract is for $1.9 Million over 12 months. Under the contract, VGX will demonstrate in vivo efficacy of novel vaccines derived from DNA plasmid-based pox virus antigens delivered using a skin micro-electroporation system.
The development of candidate countermeasures to chemical and biological warfare agents represents a major thrust of the US Government's Chemical and Biological Defense Initiative. Smallpox is classified as a CDC...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2007-09-26)
More Articles from Vaccine Weekly
- HIV/AIDS
SIV infection of natural hosts provides new insights into HIV disease complexity - Antimicrobials
New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects - Cancer Vaccines
FEATURE/Cancer Vaccine Based on Listeria Aims to Stop and Eradicate Breast Cancers - Cancer Vaccines
September Is Gynecologic Cancer Awareness Month: - Chickenpox
Novavax Announces New Discovery Program for Varicella Zoster Virus Vaccine - Flu Vaccines
GlaxoSmithKline Increases U.S. Seasonal Flu Vaccine Shipments - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
